Halting Disease Progression
in its Tracks

Now enrolling patients in the AXLerate Phase 3 trial of AVB-500 in platinum-resistant ovarian cancer.
CLICK HERE FOR WWW.CLINICALTRIALS.GOV
CLICK HERE FOR THE AXLerate PHASE 3 TRIAL


Now enrolling patients in a Phase 1b/2 trial of AVB-500 in clear cell renal cell carcinoma.
CLICK HERE FOR WWW.CLINICALTRIALS.GOV

Now enrolling patients in a Phase 1b/2 trial of AVB-500 in pancreatic adenocarcinoma.
CLICK HERE FOR WWW.CLINICALTRIALS.GOV

Halting Disease Progression in its Tracks

Now enrolling patients in the AXLerate Phase 3 trial of AVB-500 in platinum-resistant ovarian cancer.

CLICK HERE FOR WWW.CLINICALTRIALS.GOVCLICK HERE FOR THE AXLerate PHASE 3 TRIAL

Now enrolling patients in a Phase 1b/2 trial of AVB-500 in clear cell renal cell carcinoma.

CLICK HERE FOR WWW.CLINICALTRIALS.GOV

Now enrolling patients in a Phase 1b/2 trial of AVB-500 in pancreatic adenocarcinoma.

CLICK HERE FOR WWW.CLINICALTRIALS.GOV

Pipeline

AVB-500, our lead product candidate targets GAS6/AXL signaling, an important driver of cell migration and invasion in disease.

Patients

Our lead indication for AVB-500 is a registrational Phase 3 trial for the treatment of platinum resistant ovarian cancer, and we are also evaluating AVB-500 in Phase 1b/2 trials for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma.

Investors

For the latest news, corporate presentation and investor information, visit the investor section of our site.